Meanwhile, the current study confirmed that immunomodulation plays an important role in the development of DLBCL, especially immunotherapy, such as CAT-T-cell therapy, which has improved the prognosis of patients. The gene discussed is CAT; the disease is diffuse large B-cell lymphoma.